BioStock Investor Meeting: Interview with Cereno Scientific

Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of death worldwide. The company's lead candidate CS1 targets the rare disease pulmonary arterial hypertension. CEO Sten R. Sörensen told BioStock more about Cereno Scientific's lead candidate and work during BioStock Investor Meeting.

See the full interview with Cereno Scientific's CEO Sten R. Sörensen biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-cereno-scientific

This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en